Stock listing

Clearmind Medicine Inc.

Selected listing: A41YK5 · LS · EUR · DE

Clearmind Medicine Inc. (Lang & Schwarz: A41YK5), Non-Energy Minerals. Latest release Oct 7, 2026: Clearmind Advances Dialogue with U.S. Federal Government…

A41YK5:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A41YK5
Asset type: Stock
Sector: Non-Energy Minerals
Industry: Other Metals/Minerals
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Clearmind Medicine Inc.

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA

October 6, 2026

Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations

September 23, 2026

Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.

September 17, 2026

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

September 11, 2026

Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results

September 8, 2026

All Clearmind Medicine Inc. news →

Research Clearmind Medicine Inc.

Clearmind Medicine Inc. company profile

View the public company page for Clearmind Medicine Inc. on 6ix.

Clearmind Medicine Inc. news

Read company news and market updates connected to Clearmind Medicine Inc..

Clearmind Medicine Inc. investor events

Find investor webinars, events, and replay context for Clearmind Medicine Inc..